SLC5A2 and heart failure: However, SGLT2 inhibitors significantly reduced the risk of hospitalisation for heart failure or CV death (HR 0.78, 95% CI: 0.65–0.94; I2 9%) with more pronounced effect on the group of heart failure with reduced ejection fraction, whereas in participants with EF > 45%, the favourable impact of SGLT2 inhibitors did not reach the level of statistical significance (Supplementary material Figure 4).